A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer

NCT00058526 | Completed Phase 1

• 2 other identifiers: 719125/002104482
• Study Type: interventional
• Target: 61
• Locations: 5 countries
• Sites: 17

Brief Summary

Treatment phase: The purpose of this study is to evaluate the safety and the immune response elicited by a new anti-cancer therapy in patients with breast cancer in remission but who are at high risk of relapse. The study product is an immunotherapeutic consisting of the recombinant dHER2 protein combined with an immunostimulant called AS15. The study aims to determine the optimal of three different dose levels of dHER2 combined with the same fixed dose of AS15 by assessing the safety and the immune response elicited after a series of injections of the study product. Five-year follow-up phase: This part of the study aims to assess any late onset toxicity of the study treatment through yearly follow-up visits and to monitor the patients' survival and disease status up to five years after the last administration of the study treatment. The patients' immune response is also measured to assess the robustness of the immune response elicited by the study treatment.

Conditions

Neoplasms, Breast

Keywords

dHER2-AS15 ASCI; Immunotherapeutic; Dose escalation; Breast cancer

Outcome Measures

Primary Outcomes (9)

• Occurrence of dose limiting toxicity (DLT)

  During the study period (until Week 40 or 43) and the post-study follow-up period (5 years)

• Occurrence of cardiotoxicity

  During the study period (until Week 40 or 43) and the post-study follow-up period (5 years)

• Occurrence of Grade 3 or 4 adverse events

  During the study period (until Week 40 or 43) and the post-study follow-up period (5 years)

• Occurrence of solicited local and general signs and symptoms recorded by the patient on diary cards

  Period of eight days (Day 0 to Day 7) immediately after each administration of the study treatment

• Occurrence of unsolicited non-serious adverse events

  During the study period (until Week 40 or 43) and the post-study follow-up period (5 years)

• Occurrence of serious adverse events

  During the study period (until Week 40 or 43) and the post-study follow-up period (5 years)

• Hematological, biochemical (including auto-immunity) and urinalysis parameters

  During the study period (until Week 40 or 43)

• Changes in vital signs

  During the entire study period (until Week 40 or 43)

• Physical examination findings

  During the study period (until Week 40 or 43)

Secondary Outcomes (5)

• Anti-dHER2, anti-HER2 ECD (extracellular domain), anti-HER2 ICD (intracellular domain) antibody concentrations

  Two weeks after the fourth and sixth study treatment administrations (Week 6 and Week 14) and at the three and six months follow-up visit (Week 26 and Week 40). At yearly visits during the five-year follow-up period

• Anti-dHER2, anti-HER2 ECD and anti-HER2 ICD seropositivity

  Two weeks after the fourth and sixth study treatment administrations (Week 6 and Week 14) and at the three and six months follow-up visit (Week 26 and Week 40). At yearly visits during the five-year follow-up period

• In vitro functional activity response (e.g. growth inhibition of HER2-overexpressing breast tumor cells) expressed as a percentage of inhibition

  After four or six administrations of the study treatment

• Antibody-dependent cellular cytotoxicity (ADCC, % of lysis) - optionally

  After four or six administrations of the study treatment

• In vitro cellular immune response to dHER2, HER2 ECD and HER2 ICD as shown by lymphoproliferative response (expressed by stimulation index) and by secretion of interferon-γ and interleukin-5 expressed by concentration (pg/mL)

  At baseline, after Dose 4, after Dose 6, at six months follow-up visit

Study Arms (4)

Cohort 1

EXPERIMENTAL

Six doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.

Biological: Immunotherapeutic SB719125 (Primary)

Cohort 2

EXPERIMENTAL

Six doses of dHER2 (100 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.

Biological: Immunotherapeutic SB719125 (Primary)

Cohort 3

EXPERIMENTAL

Six doses of dHER2 (500 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.

Biological: Immunotherapeutic SB719125 (Primary)

Cohort 4

EXPERIMENTAL

Three doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 4, and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.

Biological: Immunotherapeutic SB719125 (Primary)

Interventions

Immunotherapeutic SB719125 (Primary) BIOLOGICAL

Intramuscular injection

Also known as: dHER2 ASCI

Cohort 1; Cohort 2; Cohort 3; Cohort 4

Eligibility Criteria

• Age: 40 Years - 70 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient must have a previous diagnosis of HER2/neu-positive breast cancer: FISH positive test (for HercepTest 2+ patients), or, HercepTest 3+ patients.
• Patients must be Stage II with at least one positive node or Stage III in remission. Patients must have had standard treatment for their cancer, including lymph node dissection and at least one course of standard adjuvant treatment.
• Patient must have completed at least one course of standard adjuvant treatment within 5 years of study entry.
• Patient may be on concurrent hormonal therapy.
• Patient must be free of recurrent breast cancer as shown by standard diagnostic tests at entry onto study.
• Patient must have a chest X-ray showing no evidence of disease.
• Patient should have an expected survival of at least 12 months.
• Written informed consent must be obtained prior to any protocol-specific procedures being performed.
• Patient must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0.
• Patient must not be pregnant and must use adequate contraception throughout the study and must plan to not bear children in the future.
• Patient must not be lactating.
• Patient must have a negative pregnancy test prior to enrollment. Pregnancy testing need not be done for patients who are \> 55 years of age, post-menopausal or surgically sterile.
• Patient must be 40 to 70 years of age inclusive. Patients younger than 40 years of age may be enrolled if they are sterile and incapable of childbearing. Chemotherapy-induced amenorrhea is not considered to be a sign of sterility.
• Patient must have adequate bone marrow reserve as indicated by: WBC ≥3000/mm3, neutrophils ≥1500/ mm3, platelets ≥100,000 mm3, lymphocytes ≥1000/mm3, and hemoglobin ≥10.0 g/dL.
• Patient must have an absolute CD4 cell count of \>200 cells/mm3.

You may not qualify if:

• Patients who are presently being treated with Herceptin or have been treated with Herceptin in the past.
• Patients who have received surgery or chemotherapy treatments within 8 weeks prior to enrollment. Patients who have received radiation therapy within 12 weeks prior to enrollment.
• Patients who have received \> 300 mg/m2 doxorubicin (cumulative dose) or \> 600 mg/m2 epirubicin (cumulative dose).
• Patients with any uncontrolled bleeding disorder or coagulation disorder or thrombocytopenia or prothrombotic disorder.
• Patients with auto-immune disease such as, but not limited to multiple sclerosis, lupus, and inflammatory bowel disease, Graves' disease and Hashimoto's disease.
• Patients with a history of previous anaphylaxis or severe allergic reaction to vaccines or unknown allergens.
• Patients with previous splenectomy or radiation to the spleen.
• Patients who have received a major organ graft (including bone-marrow transplantation).
• Patients who require chronic oral treatment (defined as more than 14 days) with immunosuppressive agents including glucocorticosteroids or other immune-modifying drugs.
• Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers or carcinoma in situ of the cervix or effectively treated malignancy that has been in remission for \> 2 years and highly likely to have been cured.
• Concurrent severe medical problems unrelated to the malignancy, which would significantly limit full compliance with the study or expose the patient to unacceptable risk.
• Patients with previous congestive heart failure or difficult-to-control hypertension. Patients with known coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy on electrocardiogram (EKG) or previous myocardial infarction.
• Patients with psychiatric or addictive disorders that may compromise the ability to give informed consent, or comply with the trial procedures.
• Patients who have received any investigational or non-registered drug or non-registered vaccine other than the study product within the 30 days preceding the first dose of study product, or who plan to receive such a drug during the study period.
• Patients who have received any immunoglobulins and/or blood products within the 3 weeks prior to study product administration.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (17)

GSK Investigational Site

Boca Raton, Florida, 33428, United States

Location

GSK Investigational Site

Buffalo, New York, 14263, United States

Location

GSK Investigational Site

Charlotte, North Carolina, 28203, United States

Location

GSK Investigational Site

Seattle, Washington, 98195, United States

Location

GSK Investigational Site

East Melbourne, Victoria, 3002, Australia

Location

GSK Investigational Site

Footscray, Victoria, 3011, Australia

Location

GSK Investigational Site

Heidelberg, Victoria, 3084, Australia

Location

GSK Investigational Site

Brussels, 1000, Belgium

Location

GSK Investigational Site

Brussels, 1200, Belgium

Location

GSK Investigational Site

Charleroi, 6000, Belgium

Location

GSK Investigational Site

Leuven, 3000, Belgium

Location

GSK Investigational Site

Lyon, 69373, France

Location

GSK Investigational Site

Paris, 75248, France

Location

GSK Investigational Site

Saint-Herblain, 44805, France

Location

GSK Investigational Site

Rome, Lazio, 00161, Italy

Location

GSK Investigational Site

Milan, Lombardy, 20141, Italy

Location

GSK Investigational Site

Perugia, Umbria, 06156, Italy

Location

Related Publications (1)

• Limentani SA, Campone M, Dorval T, Curigliano G, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Disis M, Awada A, Berliere M, Amant F, Levine E, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. Breast Cancer Res Treat. 2016 Apr;156(2):319-30. doi: 10.1007/s10549-016-3751-x. Epub 2016 Mar 18.

  PMID: 26993131 DERIVED

Related Links

• Results for study 719125/002 can be found on the GSK Clinical Study Register

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 7, 2003
• First Posted: April 9, 2003
• Study Start: March 20, 2003
• Primary Completion: September 6, 2006
• Study Completion: September 6, 2006
• Last Updated: May 15, 2017

Record last verified: 2017-05

Locations

AU (3); BE (4); FR (3); IT (3); US (4)